282 related articles for article (PubMed ID: 35028320)
1. Systematic Pan-Cancer Analysis of KLRB1 with Prognostic Value and Immunological Activity across Human Tumors.
Cheng X; Cao Y; Wang X; Cheng L; Liu Y; Lei J; Peng W; Shi D
J Immunol Res; 2022; 2022():5254911. PubMed ID: 35028320
[TBL] [Abstract][Full Text] [Related]
2. A Pan-Cancer Analysis of CD161, a Potential New Immune Checkpoint.
Zhou X; Du J; Liu C; Zeng H; Chen Y; Liu L; Wu D
Front Immunol; 2021; 12():688215. PubMed ID: 34305920
[TBL] [Abstract][Full Text] [Related]
3. The prognostic significance of KLRB1 and its further association with immune cells in breast cancer.
Xu N; Meng X; Chu H; Yang Z; Jiao Y; Li Y
PeerJ; 2023; 11():e15654. PubMed ID: 37520246
[TBL] [Abstract][Full Text] [Related]
4. Inhibiting KLRB1 expression is associated with impairing cancer immunity and leading to cancer progression and poor prognosis in breast invasive carcinoma patients.
He JR; Li D; Zhang QX; Liu T; Ding Y; Wu CY; Chen SS; Chen JL
Aging (Albany NY); 2023 Nov; 15(22):13265-13286. PubMed ID: 37988189
[TBL] [Abstract][Full Text] [Related]
5. Clinical characterization and immunosuppressive regulation of CD161 (KLRB1) in glioma through 916 samples.
Di W; Fan W; Wu F; Shi Z; Wang Z; Yu M; Zhai Y; Chang Y; Pan C; Li G; Kahlert UD; Zhang W
Cancer Sci; 2022 Feb; 113(2):756-769. PubMed ID: 34881489
[TBL] [Abstract][Full Text] [Related]
6. Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis.
Mathewson ND; Ashenberg O; Tirosh I; Gritsch S; Perez EM; Marx S; Jerby-Arnon L; Chanoch-Myers R; Hara T; Richman AR; Ito Y; Pyrdol J; Friedrich M; Schumann K; Poitras MJ; Gokhale PC; Gonzalez Castro LN; Shore ME; Hebert CM; Shaw B; Cahill HL; Drummond M; Zhang W; Olawoyin O; Wakimoto H; Rozenblatt-Rosen O; Brastianos PK; Liu XS; Jones PS; Cahill DP; Frosch MP; Louis DN; Freeman GJ; Ligon KL; Marson A; Chiocca EA; Reardon DA; Regev A; Suvà ML; Wucherpfennig KW
Cell; 2021 Mar; 184(5):1281-1298.e26. PubMed ID: 33592174
[TBL] [Abstract][Full Text] [Related]
7. Pan-Cancer Analysis of PDIA3: Identifying It as a Potential Biomarker for Tumor Prognosis and Immunotherapy.
Zhang J; Wang K; Hainisayimu T; Li H
Oxid Med Cell Longev; 2022; 2022():9614819. PubMed ID: 36046686
[TBL] [Abstract][Full Text] [Related]
8. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
Zhang X; Wang Y; A G; Qu C; Chen J
Front Immunol; 2021; 12():721030. PubMed ID: 34531868
[TBL] [Abstract][Full Text] [Related]
9.
Liang C; Chen Y; Chen S; She J; Shi Q; Wang P
Transl Cancer Res; 2023 Dec; 12(12):3641-3652. PubMed ID: 38192989
[TBL] [Abstract][Full Text] [Related]
10. Insights Into the Prognostic Value and Immunological Role of NAAA in Pan-Cancer.
Huang D; Shen J; Zhai L; Chen H; Fei J; Zhu X; Zhou J
Front Immunol; 2021; 12():812713. PubMed ID: 35069601
[TBL] [Abstract][Full Text] [Related]
11. Machine learning immune-related gene based on KLRB1 model for predicting the prognosis and immune cell infiltration of breast cancer.
Huang G; Xiao S; Jiang Z; Zhou X; Chen L; Long L; Zhang S; Xu K; Chen J; Jiang B
Front Endocrinol (Lausanne); 2023; 14():1185799. PubMed ID: 37351109
[TBL] [Abstract][Full Text] [Related]
12. Systematic Pan-Cancer Analysis Identifies TREM2 as an Immunological and Prognostic Biomarker.
Cheng X; Wang X; Nie K; Cheng L; Zhang Z; Hu Y; Peng W
Front Immunol; 2021; 12():646523. PubMed ID: 33679809
[TBL] [Abstract][Full Text] [Related]
13. Clinical and immunological characteristics of TGM3 in pan-cancer: A potential prognostic biomarker.
Zhang W; Wu C; Zhou K; Cao Y; Zhou W; Zhang X; Deng D
Front Genet; 2022; 13():993438. PubMed ID: 36685895
[No Abstract] [Full Text] [Related]
14. Pan-cancer analysis of N4-acetylcytidine adaptor THUMPD1 as a predictor for prognosis and immunotherapy.
Li K; Liu J; Yang X; Tu Z; Huang K; Zhu X
Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34762107
[TBL] [Abstract][Full Text] [Related]
15. GPC2 Is a Potential Diagnostic, Immunological, and Prognostic Biomarker in Pan-Cancer.
Chen G; Luo D; Zhong N; Li D; Zheng J; Liao H; Li Z; Lin X; Chen Q; Zhang C; Lu Y; Chan YT; Ren Q; Wang N; Feng Y
Front Immunol; 2022; 13():857308. PubMed ID: 35345673
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Significance and Immunological Role of FBXO5 in Human Cancers: A Systematic Pan-Cancer Analysis.
Liu P; Wang X; Pan L; Han B; He Z
Front Immunol; 2022; 13():901784. PubMed ID: 35720327
[TBL] [Abstract][Full Text] [Related]
17. Systematic pan-cancer analysis identifies
Chen P; Yang X; Wang P; He H; Chen Y; Yu L; Fang H; Wang F; Huang Z
Ann Transl Med; 2023 Jan; 11(2):121. PubMed ID: 36819495
[TBL] [Abstract][Full Text] [Related]
18. CXCL11 Correlates with Immune Infiltration and Impacts Patient Immunotherapy Efficacy: A Pan-Cancer Analysis.
Li Y; Han S; Wu B; Zhong C; Shi Y; Lv C; Fu L; Zhang Y; Lang Q; Liang Z; Yu Y; Tian Y
Front Immunol; 2022; 13():951247. PubMed ID: 35935945
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive Pan-Cancer Genomic Analysis Reveals PHF19 as a Carcinogenic Indicator Related to Immune Infiltration and Prognosis of Hepatocellular Carcinoma.
Zhu ZY; Tang N; Wang MF; Zhou JC; Wang JL; Ren HZ; Shi XL
Front Immunol; 2021; 12():781087. PubMed ID: 35069553
[TBL] [Abstract][Full Text] [Related]
20. Clinical and Immunological Significance of ANKRD52 in Pan-Cancer.
Yin HZ; Zhang MC; Wu H
Biochem Genet; 2024 Jan; ():. PubMed ID: 38296907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
